

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 July 14; 23(26): 4661-4846



### EDITORIAL

- 4661 Can a fibrotic liver afford epithelial-mesenchymal transition?

*Munker S, Wu YL, Ding HG, Liebe R, Weng HL*

- 4669 Impact of hepatitis C oral therapy in portal hypertension

*Libânio D, Marinho RT*

### REVIEW

- 4675 Present and future of metastatic colorectal cancer treatment: A review of new candidate targets

*Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E*

- 4689 Diarrhea after bariatric procedures: Diagnosis and therapy

*Borbély YM, Osterwalder A, Kröll D, Nett PC, Inglin RA*

### ORIGINAL ARTICLE

#### Basic Study

- 4701 Fibrinogen deficiency suppresses the development of early and delayed radiation enteropathy

*Wang J, Pathak R, Garg S, Hauer-Jensen M*

- 4712 *Helicobacter pylori* vacA genotype is a predominant determinant of immune response to *Helicobacter pylori* CagA

*Link A, Langner C, Schirrmeister W, Habendorf W, Weigt J, Venerito M, Tammer I, Schlüter D, Schlaermann P, Meyer TF, Wex T, Malfertheiner P*

- 4724 Jianpi Qingchang decoction regulates intestinal motility of dextran sulfate sodium-induced colitis through reducing autophagy of interstitial cells of Cajal

*Dai YC, Zheng L, Zhang YL, Chen X, Chen DL, Wang LJ, Tang ZP*

- 4735 *Lactobacillus acidophilus* alleviates pouchitis after ileal pouch-anal anastomosis in rats

*Xu YY, Zhang YY, He AQ, Li KY, Gao SY, Liu G*

- 4744 Effect of EPEC endotoxin and bifidobacteria on intestinal barrier function through modulation of toll-like receptor 2 and toll-like receptor 4 expression in intestinal epithelial cell-18

*Yang X, Gao XC, Liu J, Ren HY*

**Retrospective Cohort Study**

- 4752 Hospital costs, length of stay and prevalence of hip and knee arthroplasty in patients with inflammatory bowel disease

*Ehrenpreis ED, Zhou Y*

**Retrospective Study**

- 4759 Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million IU/mL: Single center, real world effectiveness and safety

*Latt NL, Yanny BT, Gharibian D, Gevorkyan R, Sahota AK*

- 4767 Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy

*Granata V, Fusco R, Setola SV, Piccirillo M, Leongito M, Palaia R, Granata F, Lastoria S, Izzo F, Petrillo A*

- 4779 Effect of initial stent position on patency of transjugular intrahepatic portosystemic shunt

*Luo SH, Chu JG, Huang H, Yao KC*

**Observational Study**

- 4788 Endoscopy is of low yield in the identification of gastrointestinal neoplasia in patients with dermatomyositis: A cross-sectional study

*Kidambi TD, Schmajuk G, Gross AJ, Ostroff JW, Terdiman JP, Lee JK*

- 4796 Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases

*Cibor D, Owczarek D, Butenas S, Salapa K, Mach T, Undas A*

- 4806 Predictors of esophageal varices and first variceal bleeding in liver cirrhosis patients

*Kraja B, Mone I, Akshija I, Koçollari A, Prifti S, Burazeri G*

- 4815 Extreme liver resections with preservation of segment 4 only

*Balzan SMP, Gava VG, Magalhães MA, Dotto ML*

- 4823 Predictive factors for body weight loss and its impact on quality of life following gastrectomy

*Tanabe K, Takahashi M, Urushihara T, Nakamura Y, Yamada M, Lee SW, Tanaka S, Miki A, Ikeda M, Nakada K*

**Prospective Study**

- 4831 Divergent expression of bacterial wall sensing toll-like receptors 2 and 4 in colorectal cancer

*Paarnio K, Väyrynen S, Klintrup K, Ohtonen P, Mäkinen MJ, Mäkelä J, Karttunen TJ*

- 4839 Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases

*Zeng J, Huang ZP, Zheng J, Wu T, Zheng RQ*

## Contents

*World Journal of Gastroenterology*  
Volume 23 Number 26 July 14, 2017

### ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Seung-Wan Ryu, MD, PhD, Associate Professor, Division of Gastrointestinal Surgery, Department of Surgery, Keimyung university, Sch Med, Daegu 700-712, South Korea

### AIMS AND SCOPE

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

### INDEXING/ABSTRACTING

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports<sup>®</sup> cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29<sup>th</sup> among 79 journals in gastroenterology and hepatology (quartile in category Q2).

### FLYLEAF

#### I-IX Editorial Board

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Dan Li*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Yuan Qi*  
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL  
*World Journal of Gastroenterology*

ISSN  
ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

LAUNCH DATE  
October 1, 1995

FREQUENCY  
Weekly

#### EDITORS-IN-CHIEF

**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

#### EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

#### EDITORIAL OFFICE

Jin-Lei Wang, Director  
Yuan Qi, Vice Director  
Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

#### PUBLISHER

Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE  
July 14, 2017

#### COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.


#### SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

#### INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION  
<http://www.f6publishing.com>



## Impact of hepatitis C oral therapy in portal hypertension

Diogo Libânio, Rui Tato Marinho

Diogo Libânio, Department of Gastroenterology, Instituto Português de Oncologia do Porto, 4200-072 Porto, Portugal

Rui Tato Marinho, Department of Gastroenterology and Hepatology, Centro Hospitalar de Lisboa Norte/Hospital Santa Maria, 1649-035 Lisbon, Portugal

Rui Tato Marinho, Faculty of Medicine, University of Lisbon, 1600-276 Lisbon, Portugal

**Author contributions:** Libânio D and Marinho RT designed and wrote this manuscript.

**Conflict-of-interest statement:** The authors declare no conflict of interest of any kind regarding this manuscript

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Diogo Libânio, MD, Department of Gastroenterology, Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. [diogo.monteiro@ipoporto.min-saude.pt](mailto:diogo.monteiro@ipoporto.min-saude.pt)  
Telephone: +35-191-0288892

Received: January 22, 2017

Peer-review started: January 24, 2017

First decision: March 16, 2017

Revised: March 28, 2017

Accepted: May 19, 2017

Article in press: May 19, 2017

Published online: July 14, 2017

### Abstract

Chronic hepatitis C is a leading cause of morbidity and

mortality, mainly related to fibrosis/cirrhosis and portal hypertension. Direct antiviral agents are highly effective and safe and can now cure > 90% of the patients. Sustained viral response (SVR) after interferon-based regimens has been associated with improvement in liver function, fibrosis and portal hypertension in a significant proportion of patients, although a point of no return seems to exist from which viral elimination is no longer capable of preventing portal hypertension progression and liver decompensation. Indeed, although SVR is associated with improvement of hepatic venous pressure gradients and therefore a decreased risk of *de novo* esophageal varices, several studies show that viral clearance does not eliminate the risk of variceal progression, liver decompensation and death in patients with pre-established portal hypertension. Although evidence about the effects of direct antiviral agents (DAAs) on clinically significant outcomes is still scarce and with short follow-up, DAAs can decrease the burden of the disease if patients are timely treated before significant fibrosis and portal hypertension develops. Studies with longer follow-up are awaited to establish the real magnitude of hepatitis C treatment on portal hypertension. Future studies should also focus on predictors of portal hypertension resolution since it can influence management and avoid unnecessary monitoring

**Key words:** Hepatitis C; Portal hypertension; Direct antiviral agents; Cirrhosis; Fibrosis; Interferon

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hepatitis C is associated with significant morbidity and mortality, mainly through portal hypertension complications. Hepatitis C treatment is associated with improvement of liver function and fibrosis, better quality of life and reduced mortality. The knowledge of the impact of viral clearance on portal hypertension is also relevant because it greatly influences clinical outcomes and can influence management after treatment. Several studies show



that the benefits on portal hypertension are higher if treatment is delivered before clinically significant portal hypertension is developed, encouraging timely and early treatment with the highly efficacious and safe direct antiviral agents.

Libânio D, Marinho RT. Impact of hepatitis C oral therapy in portal hypertension. *World J Gastroenterol* 2017; 23(26): 4669-4674 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i26/4669.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i26.4669>

## INTRODUCTION

Chronic hepatitis C is a leading cause of morbidity and mortality worldwide mainly due to complications of cirrhosis, portal hypertension and hepatocellular carcinoma. Hypertensive bleeding is the most significant complication of portal hypertension, being associated with a high early mortality (20% at 6 wk)<sup>[1]</sup>. Mortality attributed to viral hepatitis has been increasing in the last decades and viral hepatitis was the seventh leading cause of death worldwide in 2013<sup>[2]</sup>.

Direct antiviral agents (DAAs) are highly effective and safe and are changing the prognosis and burden of the disease. Sustained virologic response (SVR) is now achieved in > 90% of the patients and is associated with improvements in liver function, fibrosis and overall survival. Portal hypertension is also expected to improve with virological response, paralleling the improvements in liver inflammation and liver fibrosis. Liver transplantation due to viral hepatitis C can also decrease in the next years<sup>[3]</sup>. The knowledge of the effects of hepatitis C virus (HCV) elimination on clinically significant outcomes like portal hypertension and its complications is thus of unremarkable importance since it can influence management after SVR and is the focus of this report.

## IMPACT OF SVR IN PORTAL HYPERTENSION BEFORE DAAs

Prior to DAAs development HCV treatment was mainly recommended in patients with advanced fibrosis or cirrhosis, in order to balance treatment benefits with the risk of liver complications and treatment adverse events. SVR was achieved in 40%-60% of cases with interferon (INF) based therapies and was associated with improvements in liver fibrosis, portal hypertension, liver-related adverse events, liver-related mortality, overall mortality and decreased HCC incidence<sup>[4-7]</sup>. HCV therapy was also associated with quality of life improvement, namely reducing decompensation and hospitalization rates<sup>[8,9]</sup>.

Liver fibrosis, a major determinant of portal

hypertension, was shown to improve in several studies using paired liver biopsies<sup>[10-13]</sup> and non-invasive biomarkers<sup>[12,14]</sup>. However, a "point of no return" seems to exist for both liver fibrosis, liver function and portal hypertension. Indeed, in a large cohort of INF-treated patients, 740/1094 (68%) of the patients who achieved SVR maintained fibrosis stage 20 mo after treatment and fibrosis improved in only 277/1094 (25%)<sup>[10]</sup>.

Concerning portal hypertension, SVR was associated with a statistically significant yet modest decrease in hepatic venous pressure gradient (HVPG) 6 mo after INF-based therapy<sup>[15]</sup>. In a small study including 8 patients who achieved SVR with antiviral triple therapy there was a significant decrease in both HVPG and liver stiffness 24 wk after therapy (10.3 mmHg vs 6.1 mmHg and 21.3 kPa vs 6.4 kPa,  $P < 0.001$ ), with 5 patients (62.5%) achieving an HVPG < 6 mmHg<sup>[16]</sup>. Indirect markers of portal hypertension such as platelet count<sup>[17-19]</sup> and spleen size<sup>[17]</sup> were also shown to improve after HCV eradication in INF-treated cirrhotic patients.

Concerning clinical endpoints after HCV eradication, a prospective study with 12 years follow-up showed a lower incidence of esophageal varices in Child A cirrhotic patients with SVR (0% vs 32%-39% in the untreated/non-SVR group)<sup>[20]</sup>. A lower incidence of *de novo* esophageal varices was also reported in cirrhotic patients who achieved SVR, although the progression of variceal size was not statistically different in patients with and without SVR<sup>[21]</sup>, supporting the concept of the point of no return. Another prospective study by Di Marco *et al*<sup>[22]</sup> also showed that SVR was associated with a lower incidence of *de novo* esophageal varices in cirrhotic patients treated with PEG-INF and ribavirin (HR = 0.23, 95%CI: 0.11-0.48), although it was not associated with a decrease in variceal progression or liver decompensation in those with pre-existing varices<sup>[22]</sup>.

Petta *et al*<sup>[23]</sup> also reported a reduced incidence of *de novo* esophageal varices in patients with SVR (3.4% vs 37.4%) On the other hand, although SVR was associated with a decrease in liver decompensation and mortality at 10 years, patients with esophageal varices at baseline had an increased risk of decompensation and death. Further supporting these findings, Lens *et al*<sup>[24]</sup> recently reported that cirrhotic patients with clinically significant portal hypertension at baseline remain at risk for liver decompensation after 5 years, regardless of SVR. In these study, although SVR was associated with a non-statistically significant decrease in HVPG, a higher baseline HVPG was found as the only predictor of liver decompensation at multivariate analysis.

Besides the absence of improvement in HVPG, other factors may also influence the development of complications of portal hypertension after SVR. Indeed, Nagaoki *et al*<sup>[25]</sup> reported that portosystemic collateral shunts at baseline (assessed by CT) were associated

with exacerbation of esophageal varices and hepatic encephalopathy after SVR. Cofactors for liver disease such as obesity, alcohol consumption and hepatitis B may also contribute to minor improvement in portal hypertension after HCV eradication.

## IMPACT OF SVR IN PORTAL HYPERTENSION WITH DAAs

In order to accomplish the goal of HCV elimination as an important health public threat by 2030<sup>[26]</sup>, HCV treatment is nowadays recommended in almost all infected patients, even those without significant fibrosis<sup>[27]</sup>. This, together with the high SVR rates and the safety profile of DAAs, can change the history of HCV infection and improve clinical outcomes namely avoiding the development of portal hypertension and its improvement in patients with patients with established portal hypertension.

Liver fibrosis has also been shown to improve after INF-free DAA treatments, based on serum fibrosis biomarkers<sup>[28,29]</sup> and transient elastography<sup>[29,30]</sup>. SVR, liver function and fibrosis are undoubtedly important endpoints to assess the efficacy of HCV treatment, although portal hypertension and its complications (*i.e.*, liver decompensation and liver-related mortality) may be more adequate to assess treatment effectiveness. In fact, the knowledge of the impact of DAA treatments in portal hypertension and cirrhosis complications may influence patient management after achieving SVR. Due to the novelty of DAA INF-free therapies (and thus short follow up times) there are only few studies assessing the effects of HCV novel treatments on portal hypertension and clinical decompensation.

In patients successfully treated with DAAs, fibrosis and MELD score were shown to improve<sup>[31-33]</sup>. The decrease in necroinflammation along with fibrosis improvement can decrease intrahepatic resistance and thus portal pressure. In particular, improvement of liver inflammation, aminotransferases and liver function early during treatment can explain the rapid decreases in HVPg and liver stiffness that were found in some studies.

A well designed retrospective study conducted by the Austrian group evaluated the changes in HVPg and liver stiffness in 60 cirrhotic patients (84% Child A) treated with various combinations of DAAs<sup>[34]</sup>. SVR led to a reduction in HVPg in 80% of the patients (mean HVPg change  $-2.63 \pm 0.38$  mmHg,  $P < 0.001$ ). Importantly, in the subgroup of patients with clinically significant portal hypertension ( $\geq 12$  mmHg) at baseline, 63% achieved a HVPg decrease  $\geq 10\%$  and a decrease  $> 20\%$  or to  $< 12$  mmHg was found in 51%, at a median of 114 d after treatment. This beneficial effect was found in all strata of HVPg, although portal hypertension was less likely to improve in Child B patients. Liver stiffness and platelet counts improvements were also associated with SVR.

In another study including 33 cirrhotic patients treated with 48 wk sofosbuvir + ribavirin with clinically significant portal hypertension at baseline, 24% achieved a  $\geq 20\%$  decrease in HVPg at the end of treatment, although the median HVPg change in the entire cohort was modest ( $-0.5$  mmHg)<sup>[35]</sup>. Interestingly, higher baseline MELD score was associated with a higher HVPg response ( $P = 0.04$ ). Longer follow-up results of this trial are waited since the full effects of SVR on architectural changes and fibrosis improvement may have their effects later on time. Indeed, a more pronounced liver stiffness improvement was found between baseline and end of treatment than between end of treatment and 6 mo after, suggesting an important role of necroinflammation on the early improvements in liver stiffness<sup>[36]</sup>. Deterding *et al.*<sup>[37]</sup> suggested a two-phasic decline of portal hypertension consisting of a first rapid phase during treatment (associated with improved inflammation) followed by a slower second phase after 6-12 mo (associated with fibrosis regression). This hypothesis will surely be tested and hopefully confirmed when longer follow-up results become available.

The results of the few studies evaluating the changes in portal hypertension shortly after DAA treatment thus suggest that portal hypertension improves quickly during and after HCV eradication, which can lead to improvements in clinically significant outcomes such as variceal bleeding, ascites and encephalopathy. This theoretical concept can favor the treatment of patients with decompensated cirrhosis in whom INF-treatments were previously contraindicated. However, treatment in this setting is still a matter of debate. Indeed, although HCV eradication can decrease Child-Pugh and MELD scores in a subset of patients (decreasing the need of liver transplantation), it does not necessarily improve liver function and portal hypertension sufficiently to the point of a compensated patient with a functional live and the need for liver transplantation may persist but be delayed due to the MELD decrease (MELD purgatory).

## CONCLUSION

The available evidence shows that HCV eradication with both INF-based and DAA INF-free therapies can improve liver fibrosis and portal hypertension. The evidence of portal hypertension improvement with DAAs is still scarce but consistent with a rapid and significant improvement, which can also improve clinically significant outcomes such as variceal bleeding. However, data suggest that a point of no return exist, encouraging early treatment before the development of significant fibrosis and portal hypertension. DAA therapy, with its extremely high efficacy and safety profile, have an undoubtedly important role since it allows the cure of almost all infected patients, preventing fibrosis and portal hypertension and improving clinical outcomes.

As we have seen, patients with established portal hypertension can improve although for now there are no data about the long term effects of DAAs. The available evidence is mainly based on retrospective studies with heterogeneous populations and endpoints definitions. As randomized controlled trials with active treatment and control groups are not ethically acceptable at this time point, the best studies to answer these unsolved questions are prospective studies with well-defined inclusion and exclusion criteria, well-defined clinically significant endpoints and with long follow-up. We suggest that further studies include patients along the spectrum of HCV infection (from asymptomatic with minimal liver damage to cirrhotic patients) with stratification according to the stage of liver disease (ideally evaluated by non-invasive methods validated in HCV infection such as elastography and non-invasive markers of fibrosis). Additionally, the assessed endpoints should be clinically significant and well defined (e.g., variceal enlargement from small to large varices, *de novo* ascites, encephalopathy and hypersplenism) and follow-up should be longer than 5 years to evaluate the true impact of HCV treatment according to the stage of liver damage. Data collection should include an adequate characterization of disease stage at the beginning and at the end of follow-up (including aminotransferases, platelet count, ultrasound findings, liver stiffness, presence of ascites, varices and encephalopathy). These studies should then assess the treatment effects according to the stage of liver disease and should compare patients who achieve SVR with patients in whom these endpoint is not achieved.

Future studies should also focus on predictors of portal hypertension resolution since it can influence management and avoid unnecessary monitoring in the subset of patients with a very low probability of having clinically significant portal hypertension after treatment. Evaluation of molecular markers of extracellular matrix and hepatic stellate cell remodeling such as hyaluronic acid or alpha-2 macroglobulin may also have an investigational interest to assess if they can be a surrogate marker of the point of no return. The role of pre-existing significant porto-systemic shunts should also be evaluated.

Until the answers to these questions are available, screening for varices is still recommended in cirrhotic patients although recent Baveno VI consensus suggest that patients with Fibroscan® < 20 kPa and platelet count above 150000/μL can avoid screening endoscopy<sup>[38]</sup>. In patients who undergo screening endoscopy and no varices are found, a follow-up screening after 3 years is still recommended if SVR was achieved and there are no cofactors (a 2 year interval is advised if there is ongoing liver injury).

Concerning patients with established portal hypertension and varices before treatment, the effects of SVR on variceal progression and on bleeding rates are also still unknown and should be evaluated in

future studies. For now, those with small varices who achieved SVR and without cofactors should undergo follow-up endoscopy in 2 years, while patients with large varices should undergo primary prophylaxis and adequate management<sup>[38]</sup>. It should be also noticed that HCC surveillance should be continued in patients with F3 fibrosis or greater<sup>[27]</sup>.

In conclusion, the development of portal hypertension can be prevented and it can be improved in a significant proportion of patients as long as the treatment is delivered in a timely manner, before the point of no return. The long-term effects of DAAs on portal hypertension are not completely established and studies with longer follow-up are needed, but there is evidence from studies of the pre-DAA era that show significant benefits of SVR on portal hypertension, encouraging early treatment before significant fibrosis (F3/F4) and portal hypertension are established.

## REFERENCES

- 1 **Tripathi D**, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, Austin A, Ferguson JW, Olliff SP, Hudson M, Christie JM; Clinical Services and Standards Committee of the British Society of Gastroenterology. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. *Gut* 2015; **64**: 1680-1704 [PMID: 25887380 DOI: 10.1136/gutjnl-2015-309262]
- 2 **Stanaway JD**, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfar MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet* 2016; **388**: 1081-1088 [PMID: 27394647 DOI: 10.1016/S0140-6736(16)30579-7]
- 3 **Goldberg D**, Ditch IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, Charlton M. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. *Gastroenterology* 2017; **152**: 1090-1099.e1 [PMID: 28088461 DOI: 10.1053/j.gastro.2017.01.003]
- 4 **van der Meer AJ**, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA* 2012; **308**: 2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]
- 5 **Simmons B**, Saleem J, Heath K, Cooke GS, Hill A. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. *Clin Infect Dis* 2015; **61**: 730-740 [PMID: 25987643 DOI: 10.1093/cid/civ396]
- 6 **Smith-Palmer J**, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. *BMC Infect Dis* 2015; **15**: 19 [PMID: 25596623 DOI: 10.1186/s12879-015-0748-8]
- 7 **Morgan RL**, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Ann Intern Med* 2013; **158**: 329-337 [PMID: 23460056 DOI: 10.7326/0003-4819-158-5-201303050-00005]



- 8 **Marinho RT**, Barreira DP. Hepatitis C, stigma and cure. *World J Gastroenterol* 2013; **19**: 6703-6709 [PMID: 24187444 DOI: 10.3748/wjg.v19.i40.6703]
- 9 **Younossi Z**, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. *Gastroenterology* 2016; **150**: 1599-1608 [PMID: 26924097 DOI: 10.1053/j.gastro.2016.02.039]
- 10 **Poynard T**, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology* 2002; **122**: 1303-1313 [PMID: 11984517]
- 11 **George SL**, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. *Hepatology* 2009; **49**: 729-738 [PMID: 19072828 DOI: 10.1002/hep.22694]
- 12 **Shiffman ML**, Sterling RK, Contos M, Hubbard S, Long A, Luketic VA, Stravitz RT, Fuchs M, Sanyal AJ. Long term changes in liver histology following treatment of chronic hepatitis C virus. *Ann Hepatol* 2014; **13**: 340-349 [PMID: 24927604]
- 13 **Cammà C**, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, Marcellin P, Balart L, Alberti A, Craxi A. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. *Hepatology* 2004; **39**: 333-342 [PMID: 14767986 DOI: 10.1002/hep.20073]
- 14 **Lu M**, Li J, Zhang T, Rupp LB, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Xu F, Boscarino JA, Schmidt MA, Vijayadeva V, Gordon SC; Chronic Hepatitis Cohort Study Investigators. Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection. *Clin Gastroenterol Hepatol* 2016; **14**: 1044-1055.e3 [PMID: 26804385 DOI: 10.1016/j.cgh.2016.01.009]
- 15 **Roberts S**, Gordon A, McLean C, Pedersen J, Bowden S, Thomson K, Angus P. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. *Clin Gastroenterol Hepatol* 2007; **5**: 932-937 [PMID: 17544878 DOI: 10.1016/j.cgh.2007.02.022]
- 16 **Puente Á**, Cabezas J, López Arias MJ, Fortea JJ, Arias MT, Estébanez Á, Casafont F, Fábrega E, Crespo J. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. *Rev Esp Enferm Dig* 2017; **109**: 17-25 [PMID: 27990835 DOI: 10.17235/reed.2016.4235/2016]
- 17 **van der Meer AJ**, Maan R, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Kneegt RJ, Hansen BE, Janssen HL. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. *J Gastroenterol Hepatol* 2016; **31**: 1168-1176 [PMID: 26647353 DOI: 10.1111/jgh.13252]
- 18 **Kee KM**, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response. *Dig Dis Sci* 2013; **58**: 556-561 [PMID: 23001404 DOI: 10.1007/s10620-012-2380-4]
- 19 **Taniguchi H**, Iwasaki Y, Fujiwara A, Sakaguchi K, Moriya A, Yu PC, Takaki A, Fujioka S, Shimomura H, Shiratori Y. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. *J Gastroenterol Hepatol* 2006; **21**: 281-287 [PMID: 16460487 DOI: 10.1111/j.1440-1746.2006.04201.x]
- 20 **Bruno S**, Crosignani A, Facciotti C, Rossi S, Roffi L, Redaelli A, de Franchis R, Almasio PL, Maisonneuve P. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. *Hepatology* 2010; **51**: 2069-2076 [PMID: 20196120 DOI: 10.1002/hep.23528]
- 21 **D'Ambrosio R**, Aghemo A, Rumi MG, Primignani M, Dell'Era A, Lampertico P, Donato MF, De Nicola S, Prati GM, de Franchis R, Colombo M. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. *Antivir Ther* 2011; **16**: 677-684 [PMID: 21817189 DOI: 10.3851/IMP1807]
- 22 **Di Marco V**, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, Cammà C, Grimaudo S, Pipitone RM, Simone F, Peralta S, Arini A, Craxi A. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. *Gastroenterology* 2016; **151**: 130-139.e2 [PMID: 27039970 DOI: 10.1053/j.gastro.2016.03.036]
- 23 **Petta S**, Di Marco V, Bruno S, Enea M, Calvaruso V, Boccaccio V, Rossi S, Craxi A, Cammà C. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. *Liver Int* 2016; **36**: 1765-1773 [PMID: 27164508 DOI: 10.1111/liv.13156]
- 24 **Lens S**, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, Abalde JG, Bosch J, Sanchez-Tapias JM, Forns X, García-Pagán JC. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. *Clin Gastroenterol Hepatol* 2015; **13**: 1846-1853.e1 [PMID: 25912838 DOI: 10.1016/j.cgh.2015.04.013]
- 25 **Nagaoki Y**, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Takahashi S, Ochi H, Chayama K. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. *J Gastroenterol* 2013; **48**: 847-855 [PMID: 23053422 DOI: 10.1007/s00535-012-0679-8]
- 26 **World Health Organization**. Global health sector strategy on viral hepatitis, 2016-2021. Available from: URL: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/>, 2016
- 27 **European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.** EASL Recommendations on Treatment of Hepatitis C 2016. *J Hepatol* 2017; **66**: 153-194 [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001]
- 28 **Miyaki E**, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Hayes CN, Chayama K. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. *Hepatol Res* 2016; **46**: 758-764 [PMID: 26574180 DOI: 10.1111/hepr.12621]
- 29 **Bernuth S**, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, Kittner JM, Weyer V, Knapstein J, Schattenberg JM, Wörns MA, Galle PR, Zimmermann T. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. *Dig Liver Dis* 2016; **48**: 291-297 [PMID: 26514736 DOI: 10.1016/j.dld.2015.09.015]
- 30 **Chekuri S**, Nickerson J, Bichoupan K, Sefcik R, Doobay K, Chang S, DelBello D, Harty A, Dieterich DT, Perumalswami PV, Branch AD. Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus. *PLoS One* 2016; **11**: e0159413 [PMID: 27442255 DOI: 10.1371/journal.pone.0159413]
- 31 **Deterding K**, Höner Zu Siederdisen C, Port K, Solbach P, Sollik L, Kirschner J, Mix C, Cornberg J, Worzala D, Mix H, Manns MP, Cornberg M, Wedemeyer H. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. *Aliment Pharmacol Ther* 2015; **42**: 889-901 [PMID: 26250762 DOI: 10.1111/apt.13343]
- 32 **Aqel BA**, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, Murphy JL, Ryland K, Keaveny AP, McLemore R, Vargas HE. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. *Hepatology* 2015; **62**: 1004-1012 [PMID: 26096332 DOI: 10.1002/hep.27937]

- 33 **Foster GR**, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K; HCV Research, UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. *J Hepatol* 2016; **64**: 1224-1231 [PMID: 26829205 DOI: 10.1016/j.jhep.2016.01.029]
- 34 **Mandorfer M**, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. *J Hepatol* 2016; **65**: 692-699 [PMID: 27242316 DOI: 10.1016/j.jhep.2016.05.027]
- 35 **Afdhal N**, Everson GT, Calleja JL, McCaughan G, Bosch J, Denning J, Brainard DM, McHutchison JG, Brandt-Sarif T, An D, Charlton M, Reddy KR, Asselah T, Gane E, Forns X. LP13: Effect of long term viral suppression with sofosbuvir 1 ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. *J Hepatol* 2015; **62** (Supp 2): S269-S270
- 36 **Knop V**, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-Rust M, Sarrazin C, Zeuzem S, Welker MW. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. *J Viral Hepat* 2016; **23**: 994-1002 [PMID: 27500382 DOI: 10.1111/jvh.12578]
- 37 **Deterding K**, Schlevogt B, Port K, Cornberg M, Wedemeyer H. Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors' reply. *Aliment Pharmacol Ther* 2016; **43**: 546-547 [PMID: 26753822 DOI: 10.1111/apt.13499]
- 38 **de Franchis R**; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015; **63**: 743-752 [PMID: 26047908 DOI: 10.1016/j.jhep.2015.05.022]

**P- Reviewer:** Huang J, Dynnik VV    **S- Editor:** Qi Y    **L- Editor:** A  
**E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

